Clinical Trials Logo

Drug-drug Interaction clinical trials

View clinical trials related to Drug-drug Interaction.

Filter by:

NCT ID: NCT06381375 Recruiting - Clinical trials for Drug-drug Interaction

Drug-drug Interactions With Anti-tuberculous Drugs

Start date: April 30, 2024
Phase:
Study type: Observational

This study aims to assess the prevalence and the outcome of prescribing drugs known to have major drug-drug interactions with anti-tuberculous drugs among Kasr Alainy tuberculous patients.

NCT ID: NCT06232109 Recruiting - Clinical trials for Drug Drug Interaction

Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects

Start date: February 22, 2024
Phase: Phase 1
Study type: Interventional

The drug-drug interaction study has been designed to investigate the effect of Fluvoxamine, Itraconazole and Paroxetine on the pharmacokinetics of ASN51

NCT ID: NCT06119958 Recruiting - Clinical trials for Drug Drug Interaction

Drug-drug Interactions Between DWC202313 and DWC202314 in Healthy Subjects

Start date: October 27, 2023
Phase: Phase 1
Study type: Interventional

This is A two-arm, open-label, single-sequence, multiple oral dosings, crossover study to evaluate the safety and the pharmacokinetic interaction of DWC202313 and DWC202314 in healthy adult volunteers.

NCT ID: NCT06066060 Completed - Healthy Clinical Trials

A DDI Study of JMKX000623 and Metformin Hydrochloride

Start date: September 17, 2023
Phase: Phase 1
Study type: Interventional

A phase 1, single center, 1 sequence, 3 period, open label, multiple doses study to evaluate the drug-drug interaction of JMKX000623 tablet and metformin.

NCT ID: NCT06037564 Enrolling by invitation - HIV Clinical Trials

B-free Multistage Trial

B-free
Start date: November 13, 2023
Phase: Phase 4
Study type: Interventional

The primary objective of the study is to evaluate the efficacy of a booster-free regimen including DOR/DTG/3TC among HIV-suppressed PLWH with previous virological failure. The key secondary objectives are i) to determine whether switching to DOR / DTG / 3TC leads to lower burden of DDI compared to continuing a booster-containing regimen, and ii) to assess changes in patient perception on treatment acceptability and satisfaction, as well as health-related quality of life after a switch to booster-free ART. Qualitative sub-study: Qualitative objectives will be met using semi-structured interviews. Thirty people (15 from the intervention arm, 15 from the control arm) will be interviewed twice, at week 0 and week 48. Additional 15 individuals from the observational cohort will be interviewed once. Interviews will take place following study visits and performed using semi-structured guides. The guide for the interviews at week 48 will be based on results from analyses of the interviews conducted at week 0.

NCT ID: NCT06031454 Completed - Clinical trials for Drug Drug Interaction

Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin

Start date: September 1, 2023
Phase: Phase 1
Study type: Interventional

The drug-drug interaction study had been designed to investigate the effect of Leritrelvir on the pharmacokinetics of Midazolam, Omeprazole, Rosuvastatin and the effect of Verapamil and Rifampin on the pharmacokinetics of Leritrelvir

NCT ID: NCT05954624 Completed - Clinical trials for Drug Drug Interaction

Drug-durg Interaction of ZSP1273 With Digoxin, Rosuvastatin,Itraconazole and Probenecid

Start date: July 10, 2023
Phase: Phase 1
Study type: Interventional

The drug-drug interaction study had been designed to investigate the effect of ZSP1273 on the pharmacokinetics of digoxin, Rosuvastatin and the effect of Itraconazole and Probenecid on the pharmacokinetics of ZSP1273

NCT ID: NCT05942365 Completed - Clinical trials for Drug Drug Interaction

A Drug Interaction Study Assess the Effects of ZSP1273 Tablets on the Pharmacokinetics of Warfarin and Midazolam

Start date: June 25, 2023
Phase: Phase 1
Study type: Interventional

This study is a single-center, open label phase I clinical study to characterize the DDIs potential of ZSP1273 With Warfarin and Midazolam in Chinese healthy participants. This study also aims to evaluate the safety and tolerability of ZSP1273 in the presence of Warfarin and Midazolam.

NCT ID: NCT05860114 Completed - Clinical trials for Drug Drug Interaction

Givinostat and Metabolites Pharmacokinetics in Urine and Plasma (Part 3)

Start date: March 21, 2022
Phase: Phase 1
Study type: Interventional

Primary objective: To evaluate the plasma and urine PK of givinostat following multiple oral doses of givinostat. Secondary objective: To assess the safety and tolerability multiple oral doses of givinostat.

NCT ID: NCT05845567 Completed - Clinical trials for Drug Drug Interaction

The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2)

Start date: March 21, 2022
Phase: Phase 1
Study type: Interventional

Primary objective: To assess the potential effect of oral Clarithromycin on the single-dose pharmacokinetics of Givinostat. Secondary objective: To assess the safety and tolerability of concomitant administration of Givinostat plus Clarithromycin.